{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:42:27Z","timestamp":1784544147890,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.nrleng.2025.04.013","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:23:46Z","timestamp":1745594626000},"page":"353-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment adherence in patients with multiple sclerosis: risk factors"],"prefix":"10.1016","volume":"40","author":[{"given":"L.A.","family":"Rodr\u00edguez de Antonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fern\u00e1ndez de C\u00f3rdoba-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Herrero-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Onta\u00f1\u00f3n-Nasarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Garc\u00eda-Casta\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2025.04.013_bib0005","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2147\/PPA.S175095","article-title":"Adherence to disease-modifying therapies in patients with multiple sclerosis","volume":"12","author":"Ko\u0142tuniuk","year":"2018","journal-title":"Patient Prefer Adherence."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0010","series-title":"Multiple sclerosis: management of multiple sclerosis in primary and secondary care","year":"2014"},{"key":"10.1016\/j.nrleng.2025.04.013_bib0015","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/joim.13215","article-title":"Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis","volume":"289","author":"Piehl","year":"2021","journal-title":"J Int Med."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00005650-197903000-00004","article-title":"Active patient orientation and outcomes in hypertensive treatment: application of a socio-organizational perspective","volume":"17","author":"Schulman","year":"1979","journal-title":"Med Care."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12325-016-0363-0","article-title":"Healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with H.P. Acthar Gel\u00ae","volume":"33","author":"Gold","year":"2016","journal-title":"Adv Ther."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102016","article-title":"Noncompliance with disease modifying therapies in patients with multiple sclerosis: a qualitative analysis","volume":"41","author":"Stratos","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/PPA.S187983","article-title":"Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain","volume":"13","author":"Morillo Verdugo","year":"2019","journal-title":"Patient Prefer Adherence."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.nrl.2013.12.008","article-title":"Cumplimiento terap\u00e9utico con terapias modificadoras de la enfermedad de primera l\u00ednea en pacientes con esclerosis m\u00faltiple. Estudio COMPLIANCE","volume":"30","author":"Saiz","year":"2015","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0055","series-title":"Innovative care for chronic conditions: building blocks for action: global reports","year":"2003"},{"key":"10.1016\/j.nrleng.2025.04.013_bib0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv Ther."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ane.13301","article-title":"Medication adherence\/persistence among patients with active multiple sclerosis in Finland","volume":"142","author":"Lahdenper\u00e4","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0070","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","article-title":"Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review","volume":"269","author":"Washington","year":"2022","journal-title":"J Neurol."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0075","first-page":"1394","article-title":"Adherence to disease-modifyng therapies for multiple sclerosis","volume":"22","author":"Higuera","year":"2016","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.farma.2010.12.006","article-title":"Discontinuaci\u00f3n y adherencia a largo plazo en la terapia con interfer\u00f3n beta en pacientes con esclerosis m\u00faltiple","volume":"36","author":"Vicente Iturbe","year":"2012","journal-title":"Farm Hosp."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2011.04.026","article-title":"Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis \u2013 results of the BetaPlus observational cohort study","volume":"307","author":"Pozzilli","year":"2011","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1191\/1352458505ms1131oa","article-title":"Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns","volume":"11","author":"O\u2019Rourke","year":"2005","journal-title":"Mult Scler."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000323216","article-title":"Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project","volume":"65","author":"Arroyo","year":"2011","journal-title":"Eur Neurol."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10865-010-9247-y","article-title":"Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition","volume":"33","author":"Bruce","year":"2010","journal-title":"J Behav Med."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864211031099","article-title":"Predictors of adherence and persistence to disease-modifying therapies in multiple sclerosis","volume":"14","author":"Zanga","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1593","article-title":"Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses","volume":"17","author":"Tremlett","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.nrleng.2025.04.013_bib0115","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clinthera.2020.03.005","article-title":"Possible influence of the route of treatment administration on treatment adherence in patients with multiple sclerosis","volume":"42","author":"S\u00e1nchez Mart\u00ednez","year":"2020","journal-title":"Clin Ther."}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580825000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580825000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:08:57Z","timestamp":1747739337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580825000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2173580825000367"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2025.04.013","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment adherence in patients with multiple sclerosis: risk factors","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2025.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2023.06.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}